Hexylcaine
A local anesthetic that blocks sodium channels in nerve cell membranes to prevent pain signal transmission, used topically for anesthesia of mucous membranes in procedures such as endoscopy. It was used historically for topical anesthesia but has largely been replaced by agents with better-established safety profiles. Its mechanism of action is similar to other ester-type local anesthetics.
Moleküler Ağırlık
261,3600 g/mol
LogP
3,60
TPSA
38,30 Ų
Lipinski RO5
Geçer
Etki Mekanizması
Blocks voltage-gated sodium channels in nerve cell membranes, preventing the generation and conduction of nerve impulses. This produces reversible loss of sensation in the area of application.
Pharmacokinetics (PK)
Pharmacodynamics (PD)
Blocks voltage-gated sodium channels in nerve cell membranes, preventing the generation and conduction of nerve impulses. This produces reversible loss of sensation in the area of application.
2D Yapı
Cite this structure
Embed this structure
SMILES
CC(CNC1CCCCC1)OC(=O)c1ccccc1
InChI
InChI=1S/C16H23NO2/c1-13(12-17-15-10-6-3-7-11-15)19-16(18)14-8-4-2-5-9-14/h2,4-5,8-9,13,15,17H,3,6-7,10-12H2,1H3
Molecular Formula
C16H23NO2
HBD / HBA
1 / 3
Döndürülebilir Bağlar
6
Ağır Atomlar
19
No targets recorded
Target interaction data is not yet available for this drug.
No interactions recorded
Drug interaction data is not yet available for this compound.
No side effects recorded
Side effect data is not yet available for this drug.
Sıkça Sorulan Sorular
A local anesthetic that blocks sodium channels in nerve cell membranes to prevent pain signal transmission, used topically for anesthesia of mucous membranes in procedures such as endoscopy. It was used historically for topical anesthesia but has largely been replaced by agents with better-established safety profiles. Its mechanism of action is similar to other ester-type local anesthetics.
Blocks voltage-gated sodium channels in nerve cell membranes, preventing the generation and conduction of nerve impulses. This produces reversible loss of sensation in the area of application.
Yes, Hexylcaine is an approved drug. It has reached clinical phase 4. It is classified as a Small molecule.
References & Data Sources
- ChEMBL — European Bioinformatics Institute (EBI). CHEMBL1197. Open-access bioactivity database.
- PubChem — National Center for Biotechnology Information (NCBI). CID 10770. Chemical information database.
Data aggregated from publicly available pharmacological databases. Last updated 2026-03-04.
Embed This Widget
Add the script tag and a data attribute to embed this widget.
<script src="https://cdn.jsdelivr.net/npm/drugfyi-embed@1/dist/embed.min.js" defer></script>
<div data-drugfyi="drug" data-slug="hexylcaine"></div>Embed via iframe for maximum compatibility.
<iframe src="https://drugfyi.com/iframe/drug/hexylcaine/" width="420" height="400" frameborder="0" style="border:0;border-radius:10px;max-width:100%" loading="lazy"></iframe>Paste this URL in WordPress, Medium, or any oEmbed-compatible platform.
https://drugfyi.com/drug/hexylcaine/Add a dynamic SVG badge to your README or docs.
[](https://drugfyi.com/drug/hexylcaine/)Use the native HTML custom element.
<script src="https://cdn.jsdelivr.net/npm/drugfyi-embed@1/dist/embed.min.js" defer></script>
<drugfyi-drug slug="hexylcaine"></drugfyi-drug>